Cost of Allergy Shots Without Insurance: Freestanding vs HOPD Reality

At a transparent freestanding allergist's office, self-pay allergy shots typically cost $1,000–$4,000 per year, with a national midpoint of approximately $2,000/year based on consumer aggregator data including GoodRx, Mira, and CostHelper. That reflects CPT 95117 (injection administration) at $25–$100 cash per visit across 14–20 maintenance visits, plus two vial-preparation events (CPT 95165) at $200–$450 cash per 10-dose vial. At a hospital outpatient department, the same annual regimen can reach $5,000–$44,000+ because a facility fee is layered onto every visit in addition to the professional fee. The CMS 2025 PFS Medicare-allowed amounts — $11.97 for CPT 95117 and $13.91/dose for CPT 95165 — serve as the price-reasonability anchor: cash quotes above 10× Medicare suggest HOPD billing.

Five questions protect uninsured patients before the first appointment. First: 'Is this clinic a hospital outpatient department or provider-based facility?' — get the answer in writing; HOPD billing can multiply costs 20–40×. Second: 'Can I have a Good Faith Estimate before my first visit?' — this is a federal right under the No Surprises Act (effective January 1, 2022) for self-pay and uninsured patients. Third: 'Do you bill CPT 95165 by the Medicare 1cc rule (max 10 units per 10cc vial) or by the AMA CPT clinical-dose rule?' — this determines whether a 10cc vial generates 10 or 20+ billable units. Fourth: 'What is your cash rate for CPT 95117 and CPT 95165, published on your website or written estimate?' Fifth: 'Do you offer a financial assistance or hardship program?' Most non-profit hospital systems have charity-care programs that are not proactively disclosed.

Yes. Allergy shots are a qualified medical expense under IRS Publication 502 and are eligible for reimbursement from Health Savings Accounts (HSAs), Flexible Spending Accounts (FSAs), and Health Reimbursement Arrangements (HRAs). The CARES Act of 2020 also confirmed that FDA-approved sublingual allergen tablets and prescribed compounded sublingual immunotherapy are eligible under IRC Section 213(d). Paying with pre-tax HSA or FSA dollars effectively reduces the after-tax cost by your marginal tax rate — typically 22–32% for middle-income earners. Keep itemized receipts from every visit showing the date of service, provider, and CPT code billed. HSA holders do not need insurance to qualify for the account benefit; HSA contributions are available to anyone enrolled in a qualifying high-deductible health plan.

Transparent cash-pay pricing at freestanding allergist practices varies widely but published examples include: Midwest Allergy posts $27.50 per single-injection visit (CPT 95115), $34 per multi-injection visit (CPT 95117), and $37.50 per billable dose for vial preparation (CPT 95165) publicly on its FAQ. Aspire Allergy and Sinus posts $695 for a 58-allergen comprehensive adult testing panel. At these prices, a maintenance year (14 injection visits plus one vial replacement) runs approximately $538 in injection fees plus $375 in vial doses — under $1,000 per maintenance year. These transparent examples represent the low end; most freestanding clinics without published price lists charge 2–5× Medicare-allowed, putting a maintenance year at $1,400–$2,500.

Three reliable methods. First, call the billing department and ask directly: 'Is this location classified as a hospital outpatient department or provider-based facility?' — they are required to tell you. Second, check the CMS Hospital Price Transparency machine-readable file at the hospital system's website (mandatory since January 1, 2021): if the clinic appears there as a hospital department, it is HOPD-classified. Third, look at the clinic's physical address and billing name — if it bills under the hospital's tax ID number rather than the physician's individual NPI, it is likely HOPD. The Geisinger Scenery Park case (WPSU Public Radio, March 24, 2026) shows that HOPD-classified clinics are not always labeled as such on the door — the billing classification is an administrative designation, not a physical one.

Yes, with specific protections. Under the No Surprises Act (effective January 1, 2022), self-pay and uninsured patients have the federal right to receive a Good Faith Estimate before any scheduled service from any provider who participates in federal health care programs. If the final bill exceeds the Good Faith Estimate by $400 or more, patients can dispute the difference through the federal patient-provider dispute resolution process. The No Surprises Act also requires providers to give uninsured patients the choice between the provider's standard rates and any applicable discount or charity-care rate. However, the Act does not cap how much a provider can charge — it creates disclosure rights and dispute rights, not price controls. The best protection remains asking the HOPD question before scheduling.

Hankin et al. 2013 (J Allergy Clin Immunol 2013;131[4]:1084-91) found that adult SCIT patients had 38% lower 18-month total healthcare cost compared to matched controls ($6,637 vs $10,644), driven by reduced urgent-care, asthma, and ENT spending. Cox, Murphey, and Hankin (Immunol Allergy Clin North Am 2020;40[1]:69-85) place the direct medical cost break-even at roughly 6 years — meaning a 3-year cash-pay SCIT course does not break even purely on direct medical spend within the treatment window, but the post-treatment benefit lasts 5–10 years after the course ends. For an uninsured patient at a freestanding clinic spending ~$2,000/year ($6,000 over 3 years), the math is closer to break-even than the HOPD pricing would suggest. The 23.9% drop-out rate before the first injection (Tkacz 2021) suggests that cost anxiety — not clinical failure — is the dominant barrier to completion.